Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 142INDUSTRY 46NIH 35NETWORK 6OTHER_GOV 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Sunitinib × Clear all
NCT02626754 2018-06-26

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Taipei Veterans General Hospital, Taiwan

Phase 2 Terminated
13 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00620347 2013-06-19

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

National Cancer Center, Korea

Phase 2 Completed
25 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡